First Financial Bank Trust Division Has $273,000 Holdings in Amgen Inc. (AMGN)
First Financial Bank Trust Division grew its position in Amgen Inc. (NASDAQ:AMGN) by 4.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,587 shares of the medical research company’s stock after acquiring an additional 66 shares during the period. First Financial Bank Trust Division’s holdings in Amgen were worth $273,000 at the end of the most recent quarter.
Several other institutional investors have also recently modified their holdings of the business. Bank of New York Mellon Corp raised its position in shares of Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock worth $1,403,676,000 after acquiring an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Amgen by 1.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock worth $474,947,000 after acquiring an additional 45,403 shares during the period. UBS Asset Management Americas Inc. raised its position in shares of Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after acquiring an additional 81,362 shares during the period. Swiss National Bank raised its position in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after acquiring an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Amgen by 0.7% in the first quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock worth $242,555,000 after acquiring an additional 10,109 shares during the period. Institutional investors and hedge funds own 78.10% of the company’s stock.
A number of research analysts have weighed in on AMGN shares. Cann reiterated a “buy” rating on shares of Amgen in a research report on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG started coverage on shares of Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price target for the company. ValuEngine downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, William Blair restated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $186.39.
Amgen Inc. (AMGN) traded up 0.03% during mid-day trading on Tuesday, hitting $186.34. 842,122 shares of the stock traded hands. The company has a market cap of $135.97 billion, a price-to-earnings ratio of 16.97 and a beta of 1.35. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $191.10. The firm’s 50-day moving average is $175.99 and its 200-day moving average is $169.31.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. The business had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.84 earnings per share. Equities research analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.48%. The ex-dividend date was Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.